The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D).
Martin Reck
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Anders Mellemgaard
Consultant or Advisory Role - Boehringer Ingelheim
Sergey V. Orlov
No relevant relationships to disclose
Maciej Jerzy Krzakowski
No relevant relationships to disclose
Joachim Von Pawel
Consultant or Advisory Role - Daiichi Sankyo; Pfizer; Vertex
Maya Gottfried
No relevant relationships to disclose
Igor Bondarenko
No relevant relationships to disclose
Mei-Lin Liao
No relevant relationships to disclose
Jose Barrueco
Employment or Leadership Position - Boehringer Ingelheim
Julia Hocke
Employment or Leadership Position - Boehringer Ingelheim
Rolf Kaiser
Employment or Leadership Position - Boehringer Ingelheim
Silvia Novello
No relevant relationships to disclose
Jean-Yves Douillard
Consultant or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Merck Serono; Roche
Honoraria - Amgen; AstraZeneca